Competitive Parabolic Inhibition of Rat Tissue Kallikrein by Aprotinin
Hydrolysis of D-valyl-L-leucyl-L-arginine 4-nitroanilide (120-640 M) by rat tissue kallikrein (rK1) (3.15 nM) was studied in both the absence and the presence of increasing concentrations of aprotinin (10.4-34.6 nM), a serine protease inhibitor also known as basic pancreatic trypsin inhibitor, which inhibits trypsin, chymotrypsin, plasmin and kallikrein. The data indicate that the inhibition of rK1 by aprotinin is a parabolic competitive inhibition, with two inhibitor molecules binding to one enzyme molecule. Statistical analysis of the data supports the kinetic model proposed. The calculated values of the constants Ki and Kii (mean + SE) were 26.4 ± 5.4 nM and 16.9 ± 11.4 nM, respectively. Ki ≈ Kii, suggests that the aprotinin molecules bind to two enzyme sites with approximately the same affinity. Parabolic competitive inhibition was also reported for the inhibition of human tissue kallikrein (hK1) by aprotinin with Ki and Kii values of 16.20 nM and 1.10 nM, respectively. It is noteworthy that as the Kii < Ki, the second aprotinin molecule binds to the enzyme with a larger affinity suggesting that the second binding site was probably created or positively modulated as a consequence of the binding of the first aprotinin molecule. These results suggest different kinetic properties for the two tissue kallikreins. The second binding site for aprotinin in rK1 and also in hK1 may have important implications for the physiological activity of these enzymes. This study also presents a review of the literature on parabolic competitive inhibition.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: 2009-10-01
More about this publication?
- Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.